Royal Bank Of Canada reaffirmed their buy rating on shares of Prothena Corporation PLC (NASDAQ:PRTA) in a research report released on Friday.

A number of other research firms also recently weighed in on PRTA. ValuEngine raised Prothena Corporation PLC from a strong sell rating to a sell rating in a research note on Friday, June 2nd. Evercore ISI started coverage on Prothena Corporation PLC in a research note on Wednesday, August 16th. They set an outperform rating and a $83.00 price target on the stock. Oppenheimer Holdings, Inc. reaffirmed an outperform rating and set a $70.00 price target on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. Zacks Investment Research raised Prothena Corporation PLC from a hold rating to a buy rating and set a $66.00 price target on the stock in a research note on Friday, August 11th. Finally, BTIG Research decreased their price objective on Prothena Corporation PLC from $80.00 to $77.00 and set a buy rating for the company in a report on Friday. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $78.58.

Prothena Corporation PLC (PRTA) traded down 4.40% on Friday, hitting $64.77. The company had a trading volume of 645,417 shares. The stock’s 50-day moving average price is $59.56 and its 200 day moving average price is $56.28. Prothena Corporation PLC has a one year low of $40.58 and a one year high of $69.53. The company’s market capitalization is $2.48 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The business had revenue of $26.81 million for the quarter, compared to the consensus estimate of $16.08 million. During the same period in the prior year, the business earned ($1.18) EPS. The firm’s revenue for the quarter was up 7951.1% on a year-over-year basis. On average, analysts expect that Prothena Corporation PLC will post ($4.39) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/30/prothena-corporation-plc-prta-receives-buy-rating-from-royal-bank-of-canada.html.

In other news, Director Dennis J. Selkoe sold 3,500 shares of the company’s stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $58.11, for a total value of $203,385.00. Following the completion of the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at $368,707.95. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Christopher S. Henney sold 900 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $70.00, for a total value of $63,000.00. Following the completion of the transaction, the director now directly owns 900 shares of the company’s stock, valued at $63,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,424 shares of company stock valued at $2,226,027. 3.10% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Woodford Investment Management Ltd grew its holdings in shares of Prothena Corporation PLC by 2.6% in the second quarter. Woodford Investment Management Ltd now owns 11,400,424 shares of the biotechnology company’s stock valued at $616,991,000 after acquiring an additional 294,213 shares in the last quarter. FMR LLC grew its holdings in shares of Prothena Corporation PLC by 0.7% in the second quarter. FMR LLC now owns 5,699,234 shares of the biotechnology company’s stock valued at $308,443,000 after acquiring an additional 39,926 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Prothena Corporation PLC by 4.6% in the first quarter. Wellington Management Group LLP now owns 3,158,012 shares of the biotechnology company’s stock valued at $176,185,000 after acquiring an additional 138,979 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Prothena Corporation PLC by 7.8% in the second quarter. BlackRock Inc. now owns 2,947,512 shares of the biotechnology company’s stock valued at $159,519,000 after acquiring an additional 213,578 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Prothena Corporation PLC by 10.6% in the second quarter. State Street Corp now owns 1,181,365 shares of the biotechnology company’s stock valued at $63,932,000 after acquiring an additional 113,193 shares in the last quarter.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Stock Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related stocks with our FREE daily email newsletter.